Skip to main content

Update on the Treatment of Juvenile Idiopathic Arthritis

Current Allergy and Asthma Reports volume 13, pages 337–346 (2013)Cite this article

Abstract

Juvenile idiopathic arthritis (JIA) is one of the most common chronic diseases of childhood. Although the pathophysiology behind this disease is poorly understood, there are effective treatments for JIA based on the subtype of disease. Treatment options include non-steroidal anti-inflammatory drugs, intra-articular glucocorticoid injections, and traditional disease modifying anti-rheumatic drugs such as methotrexate. In the past decade, the use of biologic therapy in JIA, including tumor necrosis factor inhibitors, interleukin-1 inhibitors, and interleukin-6 inhibitors, has dramatically increased with promising outcomes.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Petty R, Southwood T, Manners P, et al. International League of Associations for Rheumatology classifications of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.

    PubMed  Google Scholar 

  2. Helmick C, Felson D, Lawrence R, et al. National Arthritis Data Workgroup: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25.

    Article  Google Scholar 

  3. Giannini E, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.

    PubMed  CAS  Google Scholar 

  4. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol. 2011;7:639–52.

    PubMed  Article  CAS  Google Scholar 

  5. •• Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care Res. 2011;63:465–82. This article summarizes the American College of Rheumatology treatment recommendations for juvenile idiopathic arthritis.

    Article  Google Scholar 

  6. Ruperto N, Nikishina I, Pachanov ED, et al. A Randomized, Double-Blind Clinical Trial of Two Doses of Meloxicam Compared With Naproxen in Children With Juvenile Idiopathic Arthritis. Arthritis Rheum. 2005;52:563–72.

    PubMed  Article  CAS  Google Scholar 

  7. Dowd JE, Cimaz R, Fink CW. Nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children. Arthritis Rheum. 1995;38:1225–31.

    PubMed  Article  CAS  Google Scholar 

  8. Ardoin SP, Sundy JS. Update on nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol. 2006;18:221–6.

    PubMed  Google Scholar 

  9. Vora SS, Bengtson CE, Syverson GD, Nocton JJ. An evaluation of the utility of routine laboratory monitoring of juvenile idiopathic arthritis (JIA) patients using non-steroidal anti-inflammatory drugs (NSAIDs): a retrospective review. Pediatr Rheumatol Online J. 2010;8:11.

    PubMed  Article  Google Scholar 

  10. Padeh S, Passwell JH. Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum. 1998;41:1210–4.

    PubMed  Article  CAS  Google Scholar 

  11. Marti P, Molinari L, Bolt IB, Seger R, Saurenmann RK. Factors Influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatr. 2008;167:425–30.

    PubMed  Article  Google Scholar 

  12. Zulian F, Martini G, Gobber D, et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology. 2004;43:1288–91.

    PubMed  Article  CAS  Google Scholar 

  13. Goldzweig O, Carrasco R, Hashkes PJ: Systemic adverse events following intraarticular corticosteroid injections for the treatment of juvenile idiopathic arthritis: Two patients with dermatologic adverse events and review of the literature. Semin Arthritis Rheu 2012, In press.

  14. Ilowite NT, Laxer RM. Pharmacology and Drug Therapy. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011. p. 71–126.

    Chapter  Google Scholar 

  15. Schaller JG. Corticosteroids in juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20:537–43.

    PubMed  Article  CAS  Google Scholar 

  16. •• Dewitt EM, Kimura Y, Beukelman T, et al. Consensus Treatment Plans for New-Onset Systemic Juvenile Idiopathic Arthritis. Arthrit Care Res. 2012;64:1001–10. This article summarizes consensus treatment plans from the Childhood Arthritis and Rheumatology Research Alliance for new-onset systemic juvenile idiopathic arthritis.

    CAS  Google Scholar 

  17. Ilowite NT, Sandborg CI, Feldman BM, et al. Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatr Rheumatol Online J. 2012;10:31.

    PubMed  Article  Google Scholar 

  18. Prieur AM. The place of corticosteroid therapy in juvenile chronic arthritis in 1992. J Rheumatol. 1993;37:32–4.

    CAS  Google Scholar 

  19. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis. Arthritis Rheum. 2012;64:2012–21.

    PubMed  Article  Google Scholar 

  20. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in Resistant Juvenile Rheumatoid Arthritis. Results of the U.S.A.-U.S.S.R. Double-Blind, Placebo-Controlled Trial. N Engl J Med. 1992;326:1043–9.

    PubMed  Article  CAS  Google Scholar 

  21. Woo P, Southwood TR, Prieur A-M, et al. Randomized, Placebo-Controlled, Crossover Trial of Low-Dose Oral Methotrexate in Children with Extended Oligoarticular or Systemic Arthritis. Arthritis Rheum. 2000;43:1849–57.

    PubMed  Article  CAS  Google Scholar 

  22. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Rheum. 2008;59:762–84.

    PubMed  Article  CAS  Google Scholar 

  23. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis. N Engl J Med. 2005;352:1655–66.

    PubMed  Article  CAS  Google Scholar 

  24. Silverman E, Spiegel L, Hawkins D, et al. Long-Term Open-Label Preliminary Study of the Safety and Efficacy of Leflunomide in Patients With Polyarticular-Course Juvenile Rheumatoid Arthritis. Arthritis Rheum. 2005;52:554–62.

    PubMed  Article  CAS  Google Scholar 

  25. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, et al. A 26 week randomized, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61:941–2.

    PubMed  Article  CAS  Google Scholar 

  26. Van Rossum MAJ, Fiselier TJW, Franssen MJAM, et al. Sulfasalazine in the Treatment of Juvenile Chronic Arthritis. Arthritis Rheum. 1998;41:808–16.

    PubMed  Article  Google Scholar 

  27. Van Rossum MAJ, van Soesbergen RM, Boers M, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007;66:1518–24.

    PubMed  Article  Google Scholar 

  28. Savolainen HA, Kautiainen H, Isomäki H, et al. Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumotol. 1997;24:2444–50.

    CAS  Google Scholar 

  29. Lin YT, Yang YH, Tsai MJ, Chiang BL. Long-term effects of azathioprine therapy for juvenile idiopathic arthritis. J Formos Med Assoc. 2000;99:330–5.

    PubMed  CAS  Google Scholar 

  30. Ruperto N, Ravelli A, Castell E, et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006;24:599–605.

    PubMed  CAS  Google Scholar 

  31. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. N Engl J Med. 1986;314:1269–76.

    PubMed  Article  CAS  Google Scholar 

  32. Kvien TK, Høyeraal HM, Sanstad B. Slow Acting Antirheumatic Drugs in Patients with Juvenile Rheumatoid Arthritis – Evaluated in a Randomized, Parallel 50-Week Clinical Trial. J Rheumatol. 1985;12:533–9.

    PubMed  CAS  Google Scholar 

  33. Tanaka H, Tsugawa K, Suzuki K, et al. Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr. 2007;166:1053–5.

    PubMed  Article  CAS  Google Scholar 

  34. Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr. 2004;145:856–7.

    PubMed  Article  CAS  Google Scholar 

  35. Garcia-Carrasco M, Fuentes-Alexandro S, Escárcega RO, et al. Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine. 2007;74:500–3.

    PubMed  Article  Google Scholar 

  36. Shenoi S, Wallace CE. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs. 2010;12:367–77.

    PubMed  Article  Google Scholar 

  37. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52.

    PubMed  Article  Google Scholar 

  38. Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE-JIA): a multicenter randomized open-label clinical trial. Ann Rheum Dis. 2011;70:1605–12.

    PubMed  Article  Google Scholar 

  39. Singh JA, Furst DE, Bharat A, et al. Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthrit Care Res. 2012;2012(64):625–39.

    Google Scholar 

  40. U.S. Food and Drug Administration: FDA: Cancer Warnings Required for TNF Blockers. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm. Accessed January 2013.

  41. Beukelman T, Haynes K, Curtis JR, et al. Rates of Malignancy Associated With Juvenile Idiopathic Arthritis and Its Treatment. Arthritis Rheum. 2012;64:1263–71.

    PubMed  Article  Google Scholar 

  42. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis. N Engl J Med. 2000;342:763–9.

    PubMed  Article  CAS  Google Scholar 

  43. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-Term Safety and Effectiveness of Etanercept in Children With Selected Categories of Juvenile Idiopathic Arthritis. Arthritis Rheum. 2009;60:2794–804.

    PubMed  Article  CAS  Google Scholar 

  44. Otten MH, Prince FHM, Armbrust W, et al. Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis. JAMA. 2011;306:2340–7.

    PubMed  Article  CAS  Google Scholar 

  45. Bracaglia C, Buonuomo PS, Tozzi AE, et al. Safety and Efficacy of Etanercept in a Cohort of Patients with Juvenile Idiopathic Arthritis Under 4 Years of Age. J Rheumatol. 2012;39:1287–90.

    PubMed  Article  CAS  Google Scholar 

  46. Ruperto N, Lovell DJ, Cuttica R, et al. A Randomized, Placebo-Controlled Trial of Infliximab Plus Methotrexate for the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis. Arthritis Rheum. 2007;56:3096–106.

    PubMed  Article  CAS  Google Scholar 

  47. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69:718–22.

    PubMed  Article  CAS  Google Scholar 

  48. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. N Engl J Med. 2008;359:810–20.

    PubMed  Article  CAS  Google Scholar 

  49. Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev. 2011;2, CD007649.

    PubMed  Google Scholar 

  50. Singh JA, Noorbaloochi S, Singh G. Golimumab for Rheumatoid Arthritis: A Systematic Review. J Rheumatol. 2010;37:1096–104.

    PubMed  Article  CAS  Google Scholar 

  51. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383–91.

    PubMed  Article  CAS  Google Scholar 

  52. Ruperto N, Lovell DJ, Li T, et al. Abatacept Improves Health-Related Quality of Life, Pain, Sleep Quality, and Daily Participation in Subjects With Juvenile Idiopathic Arthritis. Arthritis Care Res. 2010;62:1542–51.

    Article  Google Scholar 

  53. Ruperto N, Lovell DJ, Quartier P, et al. Long-term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis. Arthritis Rheum. 2010;62:1792–802.

    PubMed  Article  CAS  Google Scholar 

  54. Moltó A, Olivé A. Anti-Il-1 molecules: new comers and new indicators. Joint Bone Spine. 2010;77:102–7.

    PubMed  Article  Google Scholar 

  55. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med. 2009;360:2438–44.

    PubMed  Article  CAS  Google Scholar 

  56. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426–37.

    PubMed  Article  CAS  Google Scholar 

  57. Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28:129–37.

    PubMed  Article  Google Scholar 

  58. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–54.

    PubMed  Article  CAS  Google Scholar 

  59. Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as First-Line Disease-Modifying Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheum. 2011;63:545–55.

    PubMed  Article  CAS  Google Scholar 

  60. Ruperto N, Quartier P, Wulffraat M, et al. A Phase II, Multicenter, Open-Label Study Evaluating Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features. Arthritis Rheum. 2012;64:557–67.

    PubMed  Article  CAS  Google Scholar 

  61. • Ruperto N, Brunner HI, Quartier P, et al. Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. N Engl J Med. 2012;367:2396–406. This article discusses two trials of canakinumab, a new IL-1 inhibitor, for treatment in systemic juvenile idiopathic arthritis.

    PubMed  Article  CAS  Google Scholar 

  62. Lovell DJ, Giannini EH, Kimura Y, et al. Preliminary evidence for sustained bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum. 2007;56:S515.

    Google Scholar 

  63. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2013 Jan 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT00534495 NLM Identifier: NCT00534495.

  64. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.

    PubMed  Article  CAS  Google Scholar 

  65. Yokota S, Imagawa T, Mori M, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis. 2012;0:1–2.

    CAS  Google Scholar 

  66. • De Benedetti F, Brunner HI, Ruperto N, et al. Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. N Engl J Med. 2012;367:2385–95. This article discusses a randomized trial of tocilizumab, an IL-6 inhibitor, which demonstrated a significant improvement in treatment of systemic juvenile idiopathic arthritis in the tocilizumab group compared to the placebo group.

    PubMed  Article  Google Scholar 

  67. U.S. Food and Drug Administration: FDA Approves Xeljanz for rheumatoid arthritis. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm. Accessed January 2013.

  68. LaBranche TP, Jesson MI, Radi ZA, et al. JAK Inhibition With Tofacitinib Suppresses Arthritis Joint Structural Damage Through Decreased RANKL Production. Arthritis Rheum. 2012;64:3531–42.

    PubMed  Article  CAS  Google Scholar 

  69. Fleischmann R, Kremer J, Cush J, et al. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N Engl J Med. 2012;367:495–507.

    PubMed  Article  CAS  Google Scholar 

  70. Pfizer. An Open-Label Multiple Dose Study To Evaluate The Pharmacokinetics, Safety and Tolerability Of CP-690,550 In Pediatric Patients From 2 To Less Than 18 Years Of Age With Juvenile Idiopathic Arthritis (JIA). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2013 Jan 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT01513902 NLM Identifier: NCT01513902.

  71. Pfizer. A Long-Term, Open-Label Follow-Up Study Of CP-690,550 For Treatment Of Juvenile Idiopathic Arthritis (JIA). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2013 Jan 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT01500551 NLM Identifier: NCT01500551.

  72. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for Rheumatoid Arthritis Refractory to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheum. 2006;54:2793–806.

    PubMed  Article  CAS  Google Scholar 

  73. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163–72.

    PubMed  Article  Google Scholar 

Download references

Conflict of interest

Julia G. Harris declares that she has no conflict of interest.

Elizabeth A. Kessler declares that she has no conflict of interest.

James W. Verbsky declares that he has no conflict of interest.

Author information

Affiliations

  1. Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, 9000 W. Wisconsin Ave, Wauwatosa, WI, 53226, USA

    Julia G. Harris, Elizabeth A. Kessler & James W. Verbsky

Authors
  1. Julia G. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth A. Kessler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James W. Verbsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James W. Verbsky.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Harris, J.G., Kessler, E.A. & Verbsky, J.W. Update on the Treatment of Juvenile Idiopathic Arthritis. Curr Allergy Asthma Rep 13, 337–346 (2013). https://doi.org/10.1007/s11882-013-0351-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-013-0351-2

Keywords

  • Juvenile idiopathic arthritis
  • Treatment
  • Non-steroidal anti-inflammatory agents
  • Intra-articular injections
  • Glucocorticoids
  • Antirheumatic agents
  • Immunosuppressive agents
  • Methotrexate
  • Sulfasalazine
  • Biological agents
  • Tumor necrosis factor-alpha
  • Recombinant fusion proteins
  • Monoclonal antibodies
  • Immunoconjugates
  • Interleukin-1
  • Interleukin 1 receptor antagonist protein
  • Interleukin-6